filmov
tv
SABCS 2022: Updated survival results of the randomized, phase 3 study DESTINY-Breast03 + Q & A
Показать описание
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03
0:12:19
0:04:08
0:01:25
0:00:44
0:16:12
0:00:55
0:01:17
0:11:35
0:00:51
0:14:52
0:02:16
0:01:06
0:00:32
0:17:10
0:56:30
0:02:21
0:01:03
0:14:18
0:00:56
0:08:49
0:01:29
0:01:28
1:02:06
0:01:08